Navigation Links
TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
Date:3/2/2010

SALT LAKE CITY, March 2 /PRNewswire-FirstCall/ -- TechniScan, Inc. (OTC Bulletin Board: TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated 3-D breast ultrasound imaging system, today announced that in collaboration with University Medical Center Freiburg in Germany, it has launched a clinical study to assess clinical utility of TechniScan's Warm Bath Ultrasound.

TechniScan's Warm Bath Ultrasound (WBU™) system is designed for state-of-the-art ultrasound technology, used in a warm water tank, to capture 3-D images of the breast as a woman lies prone on a table.

The University Medical Center Freiburg was founded in 1457 and is one of the most prestigious and reputable hospitals in Europe due to its extensive clinical capabilities and advances in medical research. The Breast Examination Center of the Radiology Department, University Medical Center Freiburg is a regional center for women's health and it is the ideal place for the study.  

Clinicians will scan a total of at least 150 women within three defined groups: Those with normal mammography findings, those with known benign lesions, and those with known malignancies. The study includes direct comparison of TechniScan's WBU™ images against mammogram, MRI and hand held ultrasound to directly evaluate the ability of WBU™ in providing comparative diagnostic findings.  

Italian medical imaging company Esaote cooperated with TechniScan in the development of the WBU™ system and will support TechniScan's efforts in Europe and in Italy. "The Warm Bath Ultrasound system has been developed with groundbreaking science and technology," said Dr. Luigi Satragno, R&D and strategic marketing general manager of Esaote.  "We look forward to seeing the clinical studies results and to a long and productive partnership with TechniScan."

Radiologists involved in the Freiburg study will utilize TechniScan's imaging network which provides them with the ability to archive, store, and retrieve anonymous WBU™ images and relevant medical records and will discuss and compare their results with other researchers.  

"Our vision is to begin to create a database of thousands of anonymous breast images and related data," said Dave Robinson, chief executive officer at TechniScan, Inc. "This scientific database will consist of anonymous mammograms, breast MRIs and WBU™ images, along with related pathology and other information, to provide researchers around the world an unprecedented opportunity to study breast cancer. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system."

About Esaote

Esaote is one of the fastest growing medical imaging companies in the world specializing in high performance ultrasound systems and is a key investor in TechniScan, Inc.  Esaote's premium hand held ultrasound system, the MyLab 70 XVG, is integrated into TechniScan's Warm Bath Ultrasound system to provide both automated reflection imaging and to aid in hand-guided breast biopsy. As the key OEM supplier for the WBU™ system, Esaote provides TechniScan with support for engineering, regulatory and manufacturing initiatives.

About TechniScan, Inc.

Based in Salt Lake City, Utah, TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. The system uses a process called Warm Bath Ultrasound (WBU™) to provide physicians with automated, 3-D, ultrasound images of the physical structures within the breast. TechniScan's WBU™ imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.techniscanmedical.com.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company") to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Current Report on Form 8-K filed on October 16th, 2009. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE TechniScan, Inc.

Back to top

RELATED LINKS
http://www.techniscanmedical.com

'/>"/>

SOURCE TechniScan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):